Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Nephrology/Renal Transplant Recipients

Renal Transplant Recipients

4

Pipeline Programs↗

7

Active Trials↗

7

Companies Involved↗

Renal Transplant Recipients is an early-stage landscape with 4 programs across 7 companies. 3 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

78/100

Attrition Rate

17/100

Pipeline

Programs by Phase

Preclinical

No programs

Phase 1

No programs

Phase 21

TCD601

ITB-Med LLC

Phase 33

Shingrix

Shenzhen Shenxin Biotechnology Co., Ltd

Envarsus XR

University of Wisconsin, Madison

Tacrolimus Pill

Edward Geissler

Approved

No programs

Analysis

Trial Status

98

clinical trials

Completed62 · 63%

Terminated13 · 13%

Unknown status12 · 12%

Withdrawn4 · 4%

Active, not recruiting3 · 3%

Recruiting3 · 3%

Other1 · 1%

Clinical Trials

Trial Activity

98 trials

Tacrolimus C:D Ratio Measured in Renal Transplant Recipients Treated With Once-daily Prolonged-release Drugs

Recruiting·—·Phase 4·NCT06268769·300 enrolled

Shingrix in Renal Transplant Recipients

Recruiting·UUniversity of Colorado, Denver·Phase 3·NCT04128189·132 enrolled

Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.

Recruiting·MMayo Clinic·Phase 4·NCT06568549·350 enrolled

A Study of TCD601 in de Novo Renal Transplant Recipients

Active, not recruiting·IITB-Med LLC·Phase 2·NCT05669001·76 enrolled

Envarsus XR® in Adolescent Renal Transplant Recipients

Active, not recruiting·UUniversity of California, Los Angeles·Phase 4·NCT03266393·28 enrolled

RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients

Active, not recruiting·UUniversity Medical Center Groningen·Phase 4·NCT03797196·374 enrolled

European Transplant Registry of Senior Renal Transplant Recipients on Advagraf

Not yet recruiting·—·N/A·NCT02558452·1,000 enrolled

Pilot Study to Investigate a Steroid Free Immunosuppressive Regimen for Renal Transplant Recipients

Completed·UUniversity Hospital, Basel, Switzerland·Phase 4·NCT00306397·100 enrolled

Conversion of Prograf to Advagraf in Pediatric Renal Transplant Recipients

Completed·SSeoul National University Hospital·Phase 2/3·NCT01476488

24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients

Completed· Novartis logo

Novartis·Phase 4·NCT01169701·71 enrolled

Influence of Sirolimus and MMF on Vascular Function and Markers of Cellular Function in Renal Transplant Recipients

Completed·UUniversity Hospital Muenster·Phase 4·NCT00204321·80 enrolled

Calcineurin Inhibitor-Free Immunosuppression in Renal Transplant Recipients at Low Immunogenic Risk

Completed·UUniversity of Oslo School of Pharmacy·Phase 4·NCT00138970·70 enrolled

ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients

Completed· Novartis logo

Novartis·Phase 4·NCT00170846·394 enrolled

A Pilot Study Using Autologous Regulatory T Cell Infusion Zortress (Everolimus) in Renal Transplant Recipients

Completed·—·Phase 1·NCT03284242·9 enrolled

Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen in de Novo Renal Transplant Recipients.

Completed· Novartis logo

Novartis·Phase 3·NCT00238992·144 enrolled

Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)